Related references
Note: Only part of the references are listed.Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study
Scott Fung et al.
JOURNAL OF HEPATOLOGY (2017)
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany
Joerg Petersen et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial
Young-Suk Lim et al.
GUT (2016)
AASLD guidelines for treatment of chronic hepatitis B
Norah A. Terrault et al.
HEPATOLOGY (2016)
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
S. K. Sarin et al.
HEPATOLOGY INTERNATIONAL (2016)
Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients
P. Lampertico et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France
Patrick Marcellin et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Discontinuation of oral antivirals in chronic hepatitis B: A systematic review
George Papatheodoridis et al.
HEPATOLOGY (2016)
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy
George Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2016)
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
Tung-Hung Su et al.
LIVER INTERNATIONAL (2016)
The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine
Cristina Stasi et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2016)
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Henry L. Y. Chan et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Maria Buti et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Optimal management of hepatitis B virus infection - EASL Special Conference
Pietro Lampertico et al.
JOURNAL OF HEPATOLOGY (2015)
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study
Pietro Lampertico et al.
JOURNAL OF HEPATOLOGY (2015)
EXCELLENT 5-YEAR SURVIVAL IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS WITH OR WITHOUT CIRRHOSIS UNDER LONG-TERM ENTECAVIR (ETV) OR TENOFOVIR (TDF) THERAPY AND THE IMPACT OF HEPATOCELLULAR CARCINOMA (HCC)
G. Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2015)
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
George V. Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2015)
Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy
George V. Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2015)
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians
Pauline Arends et al.
GUT (2015)
Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs Lamivudine
Young-Suk Lim et al.
GASTROENTEROLOGY (2014)
Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA
Henry L. Y. Chan et al.
GASTROENTEROLOGY (2014)
Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease
Ju-Yeon Cho et al.
GUT (2014)
Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment
Wai-Kay Seto et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
LONG-TERM EFFICACY OF TENOFOVIR IN PREVIOUSLY TREATED AND NAIVE PATIENTS. RESULTS FROM THE SPANISH CHRONIC HEPATITIS B REGISTRY (CIBERHEP)
D. Tabernero et al.
JOURNAL OF HEPATOLOGY (2014)
Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment
Grace Lai-Hung Wong et al.
GASTROENTEROLOGY (2013)
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
Roeland Zoutendijk et al.
GUT (2013)
Entecavir Treatment Reduces Hepatic Events and Deaths in Chronic Hepatitis B Patients With Liver Cirrhosis
Grace Lai-Hung Wong et al.
HEPATOLOGY (2013)
Long-Term Entecavir Treatment Reduces Hepatocellular Carcinoma Incidence in Patients With Hepatitis B Virus Infection
Tetsuya Hosaka et al.
HEPATOLOGY (2013)
Efficacy of Entecavir Treatment for up to 5 Years in Nucleos(t)ide-Naive Chronic Hepatitis B Patients in Real Life
Jie Luo et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2013)
LONG TERM TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY AND THE RISK OF HEPATOCELLULAR CARCINOMA
W. R. Kim et al.
JOURNAL OF HEPATOLOGY (2013)
HEPATOCELLULAR CARCINOMA (HCC) RISK IN HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBe-) WITH OR WITHOUT CIRRHOSIS TREATED WITH ENTECAVIR: RESULTS OF THE NATIONWIDE HepNet.Greece COHORT STUDY
G. Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2013)
HEPATOCELLULAR CARCINOMA DEVELOPMENT IN HBe-NEGATIVE HEPATITIS B CIRRHOTIC PATIENTS WITH ENTECAVIR TREATMENT
Y. -C. Chen et al.
JOURNAL OF HEPATOLOGY (2013)
5-YEAR ENTECAVIR TREATMENT IN NUC-NAIVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS
P. Lampertico et al.
JOURNAL OF HEPATOLOGY (2013)
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Patrick Marcellin et al.
LANCET (2013)
Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis
Chang-Zheng Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients
Maria Buti et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients
Atsushi Ono et al.
JOURNAL OF HEPATOLOGY (2012)
Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B
Eugene R. Schiff et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/TDF, and Entecavir in Patients with Decompensated Chronic Hepatitis B Liver Disease
Yun-Fan Liaw et al.
HEPATOLOGY (2011)
Entecavir Treatment for Chronic Hepatitis B: Adaptation Is Not Needed for the Majority of Naive Patients with a Partial Virological Response
Roeland Zoutendijk et al.
HEPATOLOGY (2011)
Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patients With Hepatic Decompensation: A Randomized, Open-Label Study
Yun-Fan Liaw et al.
HEPATOLOGY (2011)
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score
Hwai-I Yang et al.
LANCET ONCOLOGY (2011)
Entecavir Treatment for up to 5 Years in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
Ting-Tsung Chang et al.
HEPATOLOGY (2010)
Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B
Ting-Tsung Chang et al.
HEPATOLOGY (2010)
Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers
Vincent Wai-Sun Wong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Severe Lactic Acidosis During Treatment of Chronic Hepatitis B with Entecavir in Patients with Impaired Liver Function
Christian M. Lange et al.
HEPATOLOGY (2009)
Long-Term Monitoring Shows Hepatitis B Virus Resistance to Entecavir in Nucleoside-Naive Patients Is Rare Through 5 Years of Therapy
Daniel J. Tenney et al.
HEPATOLOGY (2009)
Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B
Man-Fung Yuen et al.
JOURNAL OF HEPATOLOGY (2009)
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Patrick Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
